Q2 2026 saw $29.8M in net sales, 64.8% gross margin, and $1.0M net income, with strong cash reserves and no debt. Strategic growth included a successful skincare launch, telehealth expansion, and a new therapeutic candidate, while maintaining disciplined capital allocation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.